R&D Revolution in Life Sciences: Designing Data Platforms to Enable AI
In today’s rapidly evolving pharmaceutical landscape, the fusion of AI and data is not just an opportunity — it’s a necessity. As the industry seeks to compress timelines and boost productivity in drug development, the role of modern data platforms is coming into sharper focus.
How do we build data ecosystems that allow AI to deliver real value in research and development (R&D), you ask? Read on for our data transformation framework in service of smarter, faster science.
Break Down Data Silos
Pharma’s biggest barrier to AI-driven innovation isn’t a lack of models, it’s data that is not findable, accessible, interoperable and reusable (FAIR). Fragmented, inaccessible, non-interoperable data devoid of contextualizing metadata is today’s unfortunate standard. Whether locked away in legacy systems, isolated by organizational boundaries or trapped in unstructured formats, siloed data that cannot easily be interpreted and integrated slows discovery. Forward-thinking organizations are prioritizing data integration strategies that unify research, clinical and real-world data across departments and functions.
EPAM Says:
- Map your data ecosystem: Conduct a cross-functional audit to identify where critical R&D data resides — from preclinical studies to real-world evidence.
- Establish data interoperability standards: Adopt common, standardized vocabularies like Clinical Data Interchange Standards Consortium (CDISC), Health Level Seven (HL7), Fast Healthcare Interoperability Resources (FHIR) and ontologies like Semanticscience Integrated Ontology (SIO) to enable integration across research, clinical and commercial functions.
- Implement a federated data architecture: Use data mesh or data virtualization approaches to allow access without physically moving data.
Leverage Next-Gen Tools for Data Readiness
Emerging technologies for ingestion, transformation and labeling are accelerating time-to-AI-readiness. Automation in data wrangling, the rise of data mesh architectures and the use of synthetic data for model training are key enablers of scalable, reusable datasets. These tools are essential for building AI systems that adapt and learn continuously in complex R&D environments.
EPAM Says:
- Automate data pipelines: Invest in AI-native data platforms (e.g., Databricks, Snowflake with machine learning integration) that support automated ingestion and transformation at scale.
- Use active learning for labeling: Employ AI-assisted labeling tools that learn from user inputs to accelerate annotation and improve accuracy over time.
- Centralize metadata management: Deploy data cataloging tools to track provenance, quality and usage across datasets.
Lay the Groundwork for Agentic AI
Agentic AI — autonomous, task-oriented agents capable of generating hypotheses and making executive decisions — demands a robust, well-orchestrated data foundation. Establishing this foundation involves more than just centralizing information. It requires creating data contexts that are rich, machine-interpretable, traceable and actionable across the full drug development lifecycle.
EPAM Says:
- Develop semantic data layers: Layer ontologies and knowledge graphs over raw data to provide scientific context AI agents can reason over.
- Create modular data services: Design reusable APIs and microservices for accessing compound libraries, assay results and trial endpoints.
- Pilot with digital scientists: Begin with closed-loop AI agents in narrow domains (e.g., synthesis planning or biomarker discovery) to validate the architecture.
Apply AI Across the R&D Continuum
From target identification to clinical trial optimization, agentic systems are poised to impact every phase of R&D. But realizing this vision at scale depends on data platforms designed with flexibility, interoperability and governance at their core. Leaders must consider not only how data supports today’s AI use cases but how it enables tomorrow’s.
EPAM Says:
- Build cross-domain AI task orchestration: Enable agentic systems to move across boundaries — from preclinical models to patient stratification — via unified orchestration layers.
- Create governed sandboxes for experimentation: Allow AI teams to experiment with models in controlled environments with access to high-quality, compliant data.
- Measure value in business terms: Tie AI deployment to KPIs such as cycle time reduction, candidate throughput or trial recruitment speed.
Find a Trusted Partner
For CIOs, CTOs and R&D executives at the forefront of digital transformation in life sciences, the imperative is clear: Build data platforms not just for storage, but for strategic AI enablement. The rewards are high — faster discovery, smarter trials and ultimately, better outcomes for patients. The right engineering and strategy partner can help you reap the benefits.
EPAM Says: Hello!
